Abstract
In France, medicine prices are set by the French Healthcare Products Pricing Committee (CEPS) through negotiations with pharmaceutical industries. Sales volumes is one of the main price determinants. It may lead to major impact in the final pricing agreement in particular on a potential managed-entry agreement structure or on market shares assumptions. This analysis aims to evaluate the accuracy of the sales forecasts provided by the manufacturers to the CEPS when starting price negotiations. This retrospective study includes in- and out-patient medicines which reimbursement decision for their first indication was published in 2015 or 2016 in the Official Gazette. It excludes biosimilars, generics, medicines with new indication or new pharmaceutical form which reimbursement occurred within the 36 first months sales, medicines funded through a DRG and those which already had sales before reimbursement. The sales forecasts are extracted from the economic dossier submitted by the manufacturers, and actual sales volume from the GERS database. Descriptive statistics are used to compare the difference between the sales forecasts and the sales volume in a rolling period of 36 months. Thirty-eight new medicines fulfill the inclusion criteria and thus have been included in the final analysis, among the eighty-one medicines that were reimbursed for their first indication in 2015 or 2016. The actual sales volume are in general lower than the sales forecasts (median gap of -30,5% over three years). The median gap between the sales volume and the forecasts is -42.9 %, -41.5 % and -41.8 % for respectively the first, second and third year of marketing. Inaccurate forecasts may distort medicines expenditure due to inadequate managed-entry agreements build on these data such as price volume agreements. Payers should mitigate these discrepancies and thus, favor simple discounts or ex-post mechanisms to increase health-spending predictability.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.